About Us

We believe in people and their potential. We envision a world where everyone is operating at peak mental performance, free from the stresses and imbalances that hold us back.

MISSION

Empowering human potential. 

Using evidence-informed research, we are on a mission to unlock human performance and empower people to achieve their full potential. Through end to end research, extraction, formulation and delivery, we aspire to define and standardize the future of modern medicine.

OUR STORY

HAVN Life is a part of a global community taking an active part in supporting research addressing mental health disorders. Working with Veterans and thought leaders in the military, HAVN Life is developing innovative formulations to support clinical trials addressing PTSD recovery and other trauma related disorders.

We are focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.

With an extensive team of industry leaders with 20+ years of experience in this space, HAVN Life is formulating the next generation of medicine using psychedelic compounds. 

Our Values

At HAVN Life, we are dedicated to innovation, diversity and implementing the highest standards of the scientific method.

We have a deep-seated drive to help others and share our knowledge. With a range of standardized, quality-controlled formulated products, HAVN Life will provide cutting edge technology and intellectual property for mental health and human performance with a strong focus on psychoactive natural healthcare products.

Our Team

Collaboration across disciplines

Creating positive patient experiences and mental health outcomes

Vic Neufeld

Executive Chairman

CEO of Aphria for 5 years during large scale build up to one of the leading cannabis producers in the world.

Tim Moore

Chief Executive Officer

Former CEO of Green Growth Brands, from IPO through to Jan 2019, leading the Company to ~$1 Billion market cap.

Gary Leong

Chief Science Officer

Former Chief Scientific Officer at Aphria Inc. where he established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs & Research and Development functions.

Gordon Clissold

Chief Financial Officer

Over 20 years of experience as an operational and financial manager, in both public and private companies, with a career experience spanning technology, manufacturing, wholesale distribution, and professional services.

Dr. Ivan Casselman

Chief Psychedelic Officer

Extensive nutraceutical formulation experience, with several products available in legal cannabis markets in North America.

Alexzander Samuelsson

Chief Research Officer

Lead chemist of a publicly traded extraction company, Alexzander developed intellectual property and patented methods in the extraction of cannabis oils.

Jenna Pozar

Chief Operations Officer

18 years of NHP marketing and logistics experience, including Jamieson Wellness and Body Plus. Responsible for the growth and planning for 200+ retail store accounts and three national chains, with a portfolio of eight natural health and performance brands.

Juliana Mollica

Director of Innovation and Quality Assurance

Led projects as the quality assurance and compliance manager for cannabis and pharmaceutical companies to ensure maintenance of GMP requirements, developing QMS for multi-site projects, compliance training programs, and increasing compliance and quality rates.

Rick Brar

Vice Chairman

CEO & Chairman of Brains Bioceutical Corp. A global manufacturer and distributor of Cannabinoid API.

Tim Laidler

Director

Executive Director of the Institute for Veterans Education and Transition at UBC. The institute focuses on supporting the needs of veterans in the community as well as supporting cutting edge research with Veterans.

Havn Life Board

Dennis Staudt

Director

Financial and business expert. As CPA with 22 years as a partner in PricewaterhouseCooper's Audit and Assurance Group. Vice-President of a family-owned farming operation, Staudt Farms.

Dr. David Mokler

Advisor

Expert specialist in neuropharmacology, psychopharmacology, substance abuse, drug abuse, brain development, dopamine and serotonin including work relevant to the 5HT2a receptors in psychedelics

Sheila Copps

Advisor

The Honourable Sheila Copps was the first woman to ever hold the position of Deputy Prime Minister and served for ten years in the federal cabinet.

Allan Oberman

Advisor

Served as CEO for Concordia International, an international speciality pharmaceutical company with sales in 90 countries and over 200 medicines.

David King

Advisor

Drug science and policy expert who received the Dr Abbas Khan Medal by King’s College London for ‘outstanding humanitarian contributions to the service of society’. Also Founder of the Breaking Convention, Europe’s largest academic conference on psychedelic drug research.

Path To Market

regulated Route To Market

.  

.
.
.
.
.

Direct To Consumers

Natural Health Products

  .  .  

.
.
.
.
.

Contract Manufacturer
(White Label)

Natural Health Products

.
.
.
.
.

Direct To Consumers

Contract Manufacturer
(White Label)

ReSTRICTED COMPOUND Route To Market

.  

.
.
.
.
.

Supply Academic Research
(Dealers License)

Psychedelic Extraction and Supply

  

.
.
.
.
.

Formulate Microdosing Therapies
(Pre-Clinical Trials)

Psychedelic Extraction and Supply

.
.
.
.
.

Supply Academic Research
(Dealers License)

Formulate Microdosing Therapies
(Pre-Clinical Trials)

Mushroom Market

Demand for mushrooms is growing. The market for mushrooms such as Lion’s Mane, Cordyceps, Reishi, and Chaga is rising. These mushrooms have numerous benefits that we are still discovering today. Mushrooms are an extremely beneficial and nutritious functional food that will continue to be a key player in the global functional food market. The market is set to reach a value of $34.3 Billion USD by 2024.

Growing Mushroom Market

Global Revenue in 2016 – 2024

The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024)

The market studied is expected to experience huge demand for Reishi and Cordyceps and this is why HAVN Life has decided to pursue formulations with these mushrooms.

Roadmap

2020

HAVN logo
HAVN Labs

One of the first companies to receive permission from Health Canada to work with psilocybin

2020

2020

havn logo
HAVN Labs

Finalize Pre-Clinical Protocols for Compound Extraction and Supply

2020

2021

havn logo
HAVN Retail

Manufacture & Distribute at Scale

2021

2021

havn logo
HAVN Labs

Licensed Dealer Approval

2021

2021

havn logo
HAVN Labs

Supply Clinical Trials with GMP Certified Psychedelic Compounds

2021

2021

havn logo
HAVN Labs

Formulate Psychedelic Therapies for Clinical Trials

2021

2022+

havn logo
HAVN Retail

Expansion of Distribution Channels

2022+

2022+

havn logo
HAVN Labs

Publish Analytical Method Results

2022+
Scroll to Top